Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 3/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734783 | 0.91 | PTPN11 (0.66) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656101 | 0.89 | PTPN11 (0.57) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656076 | 0.89 | PTPN11 (0.57) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12655708 | 0.89 | PTPN11 (0.57) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656102 | 0.89 | PTPN11 (0.44) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656000 | 0.89 | PTPN11 (0.61) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12655959 | 0.89 | PTPN11 (0.67) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656099 | 0.85 | LTB4R2 (0.53) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656096 | 0.82 | PTPN11 (0.66) | PTPN11PTPRORARBRARARARG | |
| SCHEMBL12656209 | 0.82 | PTPN11 (0.53) | PTPN11PTPRORARBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947851-B2 | 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors | MERCK SERONO SA (CH) | 2011-05-24 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | PTPRS, PTPRZ1, PTP4A1 | PTPN11 38/4885PTPRO 4/4885RARB 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.